Hopp til hovedinnhold

Levercirrhose og kronisk leversvikt

Sist revidert:
Sist revidert av:
Definisjon:
Cirrhose representerer et sent stadium av en progressiv, irreversibel tilstand som ødelegger hele leverens normale arkitektur og medfører leversvikt
Forekomst:
Ca. 10 tilfeller per 100.000. Alkoholmisbruk antas å være skyld i 75-80% av tilfellene med levercirrhose
Symptomer:
Mange er asymptomatiske i tidlig fase. Symptomer kan være nedsatt matlyst, vekttap, svakhet, slapphet
Funn:
Kan foreligge en rekke ulike funn: ascites, teleangiektasier, caput medusa, tremor, hepatomegali, ikterus
Diagnostikk:
Leverfunksjonsprøver viser nedsatt funksjon, ev. serologi, ev. ferritin, ev. ultralyd, ev. leverbiopsi
Behandling:
Målet er å forsinke eller reversere progresjonen av leversykdommen, ev. levertransplantasjon
  • Nasjonal behandlingstjeneste for organtransplantasjon, Oslo universitetssykehus HF, nettsted 
  1. Smith A, Baumgartner K, Bositis C. Cirrhosis: diagnosis and management. Am Fam Physician. 2019 Dec 15;100(12):759-770. PubMed  
  2. Goldberg E, Chopra S. Cirrhosis in adults: Etiologies, clinical manifestations, and diagnosis. UpToDate, Feb 12, 2021. UpToDate  
  3. Goldberg E, Chopra S. Cirrhosis in adults: Overview of complications, general management, and prognosis. UpToDate, Sep 13, 2021. www.uptodate.com. UpToDate  
  4. Paulssen EJ. Når leveren svikter. Indremedisineren. Publisert 24.01.2019. indremedisineren.no  
  5. Haukeland JW. Oppfølging av pasienter med levercirrhose. Indremedisineren, 24.01.2019 . indremedisineren.no  
  6. Eskesen AN, Bjoro K, Aandahl EM, Line PD, Melum E. Low use of surveillance and early diagnosis of hepatocellular carcinoma in Norway–a population-based cohort study. Cancer Epidemiol. 2014;38(6):741-7. PubMed  
  7. Haukeland JW, Lorgen I, Schreiner LT, Frigstad SO, Brandsaeter B, Bjoro K, et al. Incidence rates and causes of cirrhosis in a Norwegian population. Scand J Gastroenterol. 2007;42(12):1501-8. PubMed  
  8. Dolman GE, Kennedy PTF. Cirrhosis. BMJ Best Practice, last updated 24 Oct 2019.
  9. National Institute for Health and Care Excellence. Cirrhosis in over 16s: assessment and management. NICE guideline [NG50]. July 2016. Accessed May 28, 2019. www.nice.org.uk  
  10. Asrani SK, Kamath PS. Natural history of cirrhosis. Curr Gastroenterol Rep. 2013;15(2):308. PubMed  
  11. D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol. 2006;44(1):217–231.
  12. Harrison SA, Bacon BR. Relation of hemochromatosis with hepatocellular carcinoma: epidemiology, natural history, pathophysiology, screening, treatment, and prevention. Med Clin North Am 2005; 89: 391-409. PubMed  
  13. Di Martino M, Marin D, Guerrisi A, et al. Intraindividual comparison of gadoxetate disodium-enhanced MR imaging and 64-section multidetector CT in the detection of hepatocellular carcinoma in patients with cirrhosis. Radiology. 2010; 256: 806-16. PubMed  
  14. Simonovsky V. The diagnosis of cirrhosis by high resolution ultrasound of the liver surface. Br J Radiol 1999; 72: 29-34. British Journal of Radiology  
  15. Geng XX, Huang RG, Lin JM, et al. Transient elastography in clinical detection of liver cirrhosis: a systematic review and meta-analysis. Saudi J Gastroenterol. 2016;22(4):294–303.
  16. Kutala BK, Guedj J, Asselah T, Boyer N, Mouri F, Martinot-Peignoux M, et al. Impact of treatment against hepatitis C virus on overall survival of naive patients with advanced liver disease. Antimicrobial agents and chemotherapy. 2015;59(2):803-10. PubMed  
  17. Lackner C, Spindelboeck W, Haybaeck J, Douschan P, Rainer F, Terracciano L, et al. Histological parameters and alcohol abstinence determine long-term prognosis in patients with alcoholic liver disease. Journal of hepatology. 2017;66(3):610-8. PubMed  
  18. Kamal S, Khan MA, Seth A, et al. Beneficial Effects of Statins on the Rates of Hepatic Fibrosis, Hepatic Decompensation, and Mortality in Chronic Liver Disease: A Systematic Review and Meta-Analysis. Am J Gastroenterol 2017. pmid:28585556 PubMed  
  19. Haukeland JW, Bjøro K. Når hjernen svikter ved leversvikt. Tidsskr Nor Lægeforen 2007; 127: 1490. PubMed  
  20. Kanwal F, Kramer J, Asch SM, et al. An explicit quality indicator set for measurement of quality of care in patients with cirrhosis. Clin Gastroenterol Hepatol 2010; 8: 709-17. PubMed  
  21. Licata G, Tuttolomondo A, Licata A, et al. Clinical trial: high-dose furosemide plus small-volume hypertonic saline solutions vs. repeated paracentesis as treatment of refractory ascites. Aliment Pharmacol Ther 2009; 30: 227-35. PubMed  
  22. Helsedirektoratet. Spontan bakteriell peritonitt. Nasjonale retningslinjer. Antibiotika i sykehus. Sist oppdatert 08.01.2018. helsedirektoratet.no  
  23. Sharma BC, Sharma P, Lunia MK, et al. A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy. Am J Gastroenterol. 2013;108:1458-1463. PubMed  
  24. Cordoba J, Lopez-Hellin J, Planas M, Sabin P, Sanpedro F, Castro F, et al. Normal protein diet for episodic hepatic encephalopathy: results of a randomized study. J Hepatol 2004; 41: 38-43. PubMed  
  25. Bass NM, Mullen KD, Sanyal A, et al. Rifaximin treatment in hepatic encephalopathy. New Engl J Med 2010; 362: 1071-81. PubMed  
  26. Gluud LL, Vilstrup H, Morgan MY. Non‐absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis. Cochrane Database of Systematic Reviews 2016, Issue 5. Art. No.: CD003044. The Cochrane Library  
  27. Jutabha R, Jensen DM, Martin P, Savides T, Han SH, Gornbein J. Randomized study comparing banding and propranolol to prevent initial variceal hemorrhage in cirrhotics with high-risk esophageal varices. Gastroenterology 2005; 128: 870-81. Gastroenterology  
  28. Runyon BA; AASLD Practice Guidelines Committee. Management of adult patients with ascites due to cirrhosis: an update. Hepatology 2009; 49: 2087-2107. PubMed  
  29. Chavez-Tapia NC, Barrientos-Gutierrez T, Tellez-Avila FI, Soares-Weiser K, Uribe M. Antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding. Cochrane Database Syst Rev 2010; (9): CD002907. Cochrane (DOI)  
  30. Francoz C, Durand F, Kahn JA, Genyk YS, Nadim MK. Hepatorenal Syndrome. Clin J Am Soc Nephrol. 2019 May 7;14(5):774-781. Epub 2019 Apr 17. PMID: 30996046 PubMed  
  31. Gines A, Escorsell A, Gines P, Salo J, Jimenez W, Inglada L, et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 1993; 105: 229-36. Gastroenterology  
  32. Arroyo V, Gines P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology 1996; 23: 164-76. PubMed  
  33. Jepsen P, Ott P, Andersen PK, Sørensen HT, Vilstrup H. Risk for hepatocellular carcinoma in patients with alcoholic cirrhosis: a danish nationwide cohort study. Ann Intern Med 2012; 156: 841-7. Annals of Internal Medicine  
  34. Centers for Disease Control and Prevention. Alcohol-attributable deaths and years of potential life lost-United States, 2001. MMWR Morb Mortal Wkly Rep 2004; 53: 866-70. PubMed  
  35. Martin P, DiMartini A, Feng S, et al. Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Hepatology. 2014;59(3):1144–1165.
  • Terje Johannessen, professor i allmennmedisin, Trondheim (tilpasning til NEL)